Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57699 | 0.90 | IDO1 (0.46) | ALDH1A1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL17931867 | 0.87 | METAP2 (0.49) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL12926852 | 0.87 | METAP2 (0.41) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL17931887 | 0.86 | KDM4E (0.47) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL21767732 | 0.86 | METAP2 (0.63) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL85419 | 0.84 | TSHR (0.56) | METAP2ALOX12ALDH1A1CYP3A4HIF1A | |
| SCHEMBL8344722 | 0.83 | METAP2 (0.53) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL1006162 | 0.82 | TSHR (0.55) | METAP2ALOX12ALDH1A1CYP3A4HPGD | |
| SCHEMBL19603066 | 0.82 | METAP2 (0.59) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL29729655 | 0.81 | PARP1 (0.58) | METAP2PLAUNCF1ALOX12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | SIERRA SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | SIERRA SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-2504418-B1 | DETERGENTS OR CLEANING AGENTS CONTAINING A BLEACH-ENHANCING TRANSITION METAL COMPLEX WHICH IS OPTIONALLY PRODUCED IN SITU | HENKEL AG & CO KGAA (DE) | 2017-02-15 | — | — | EP | disclosed |
| EP-2504419-B1 | DETERGENTS OR CLEANING AGENTS CONTAINING A BLEACH-ENHANCING TRANSITION METAL COMPLEX WHICH IS OPTIONALLY PRODUCED IN SITU | HENKEL AG & CO KGAA (DE) | 2017-02-01 | — | — | EP | disclosed |
| EP-2504419-B1 | DETERGENTS OR CLEANING AGENTS CONTAINING A BLEACH-ENHANCING TRANSITION METAL COMPLEX WHICH IS OPTIONALLY PRODUCED IN SITU | HENKEL AG & CO KGAA (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-9199924-B2 | Process for the preparation of urethanes | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199924-B2 | Process for the preparation of urethanes | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| EP-2504419-A1 | DETERGENTS OR CLEANING AGENTS CONTAINING A BLEACH-ENHANCING TRANSITION METAL COMPLEX WHICH IS OPTIONALLY PRODUCED IN SITU | Henkel AG & Co. KGaA (DE) | 2012-10-03 | — | — | EP | disclosed |
| WO-2012020028-A1 | METHOD FOR PRODUCING URETHANES | BAYER MATERIALSCIENCE AG (DE) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011064158-A1 | DETERGENTS OR CLEANING AGENTS CONTAINING A BLEACH-ENHANCING TRANSITION METAL COMPLEX WHICH IS OPTIONALLY PRODUCED IN SITU | HENKEL AG & CO. KGAA (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011064158-A1 | DETERGENTS OR CLEANING AGENTS CONTAINING A BLEACH-ENHANCING TRANSITION METAL COMPLEX WHICH IS OPTIONALLY PRODUCED IN SITU | HENKEL AG & CO. KGAA (DE) | 2011-06-03 | — | — | WO | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| WO-2004007461-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-01-22 | — | — | WO | disclosed |
| US-20030049287-A1 | Catechol oximes and their use in cosmetic and dermatological preparations | HAARMANN & REIMER GMBH (DE) | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | METAP2 1832/4885PLAU 2218/4885NCF1 2693/4885 |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PARK7, COQ8A, NLN | METAP2 1832/4885PLAU 2218/4885NCF1 2693/4885 |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | TERT, TERF2, RNGTT | METAP2 1330/4885PLAU 3003/4885NCF1 2599/4885 |
| US-20030049287-A1 | Catechol oximes and their use in cosmetic and dermatological preparations | TYR, LPO, COMT | METAP2 1921/4885PLAU 4064/4885NCF1 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.